Meet-URO 23a

Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination. The MeeT-URO 23a SUB-STUDY I-RARE NEMESIA (Non clEar MEtaStatic renal cell carcinoma pembrolIzumab Axitinib), subgroup analysis of I-RARE observational study (Meet-URO23)

Stato

Studio in apertura - Raccolta adesioni in corso

Patologia

Rene

Tipologia

Osservazionale

Centro Coordinatore: Policlinico Universitario Campus Bio Medico - Roma
Principal Investigator: Daniele Santini
Sub Investigator: Marco Stellato
Study Coordinator: -

Documentazione disponibile